Celularity Balance Sheet Health
Financial Health criteria checks 0/6
Celularity has a total shareholder equity of $27.8M and total debt of $41.0M, which brings its debt-to-equity ratio to 147.4%. Its total assets and total liabilities are $135.5M and $107.7M respectively.
Key information
147.4%
Debt to equity ratio
US$41.00m
Debt
| Interest coverage ratio | n/a |
| Cash | US$467.00k |
| Equity | US$27.81m |
| Total liabilities | US$107.68m |
| Total assets | US$135.49m |
Recent financial health updates
Recent updates
Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%
Feb 14
Celularity appoints Adrian Kilcoyne as chief medical officer
Oct 03Celularity falls after announcing fund raising deal
Sep 15Celularity falls 10% on deal for $150M common stock offering
Sep 08Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers
Jul 27Financial Position Analysis
Short Term Liabilities: CELU's short term assets ($17.7M) do not cover its short term liabilities ($67.9M).
Long Term Liabilities: CELU's short term assets ($17.7M) do not cover its long term liabilities ($39.8M).
Debt to Equity History and Analysis
Debt Level: CELU's net debt to equity ratio (145.7%) is considered high.
Reducing Debt: CELU's debt to equity ratio has increased from 7.7% to 147.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CELU has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CELU has less than a year of cash runway if free cash flow continues to grow at historical rates of 6.1% each year.